- Home
- HRMY vs OMCL Comparison
HRMY vs OMCL Comparison
Compare HRMY & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- OMCL
- Stock Information
- Founded
- HRMY 2017
- OMCL 1992
- Country
- HRMY United States
- OMCL United States
- Employees
- HRMY N/A
- OMCL N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- OMCL Computer Manufacturing
- Sector
- HRMY Health Care
- OMCL Technology
- Exchange
- HRMY Nasdaq
- OMCL Nasdaq
- Market Cap
- HRMY 1.6B
- OMCL 1.5B
- IPO Year
- HRMY 2020
- OMCL 2001
- Fundamental
- Price
- HRMY $34.05
- OMCL $25.78
- Analyst Decision
- HRMY Strong Buy
- OMCL Buy
- Analyst Count
- HRMY 8
- OMCL 6
- Target Price
- HRMY $52.88
- OMCL $45.83
- AVG Volume (30 Days)
- HRMY 701.6K
- OMCL 725.6K
- Earning Date
- HRMY 05-06-2025
- OMCL 05-06-2025
- Dividend Yield
- HRMY N/A
- OMCL N/A
- EPS Growth
- HRMY 13.13
- OMCL N/A
- EPS
- HRMY 2.62
- OMCL 0.45
- Revenue
- HRMY $744,852,000.00
- OMCL $1,135,755,000.00
- Revenue This Year
- HRMY $20.06
- OMCL $3.75
- Revenue Next Year
- HRMY $18.40
- OMCL $4.42
- P/E Ratio
- HRMY $13.10
- OMCL $57.25
- Revenue Growth
- HRMY 20.62
- OMCL 3.00
- 52 Week Low
- HRMY $26.47
- OMCL $22.66
- 52 Week High
- HRMY $41.61
- OMCL $55.75
- Technical
- Relative Strength Index (RSI)
- HRMY 69.53
- OMCL 28.65
- Support Level
- HRMY $29.82
- OMCL $22.66
- Resistance Level
- HRMY $30.61
- OMCL $32.18
- Average True Range (ATR)
- HRMY 1.12
- OMCL 1.17
- MACD
- HRMY 0.74
- OMCL -0.46
- Stochastic Oscillator
- HRMY 92.78
- OMCL 32.77
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.